Get started
Author

Jing Sun

ORCID: 0009-0003-3393-247X
Observed ORCID: 0009-0003-3393-247X
OpenAlex ID: A5015575990
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · Cancer Discovery · 120
Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity
2023 · Kang Le, Jing Sun, et al. · Blood Advances · 34
CDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett’s-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions
2024 · Jing Sun, Jorge L. Sepulveda, et al. · Cellular and Molecular Gastroenterology and Hepatology · 7
PDF
Gallbladder disease and colorectal cancer: a two-sample bidirectional Mendelian randomization study
2026 · Qiang Hu, Jing Sun · Discover Oncology · 1
Considerations on Genetic and Treatment Factors in NSCLC Segmentectomy Outcomes
2025 · Qiang Hu, Jing Sun · Journal of Thoracic Oncology · 1
Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · 1
Supplementary methods from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · 1
Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Table 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 5 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Table 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Table 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2026 · Justin F. Gainor, Manish R. Patel, et al.
Sa1214: DEVELOPMENT AND MOLECULAR CHARACTERIZATION OF SMALL INTESTINE ADENOMAS AND ADENOCARCINOMAS IN A MURINE MODEL CARRYING KRAS12D AND CDKN2A/P16-LOSS TARGETING LGR5 PROGENITOR CELLS
2025 · Tyler Seckar, Jing Sun, et al. · Gastroenterology
Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Table 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 5 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al.
Supplementary Figure 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al.
Works count: 36
Citation count: 165
H-index: 3
I10-index: 2
Year
Topic
Type